欢迎访问中国现代中药网站

作者中文名	作者英文名	单位中文名	单位英文名	E-Mail
宋珂	SONG Ke	北京中医药大学东直门医院中医内科学教育部和北京市重点实验室，北京100700	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
侯彦宏	HOU Yan-hong	中国中医科学院中医药发展研究中心，北京100700	Research Center for Chinese Medicine Development，China Academy of Chinese Medical Sciences，Beijing 100700，China
苏都娜	SU Du-na	内蒙古赤峰市安定医院，内蒙古赤峰024000	China Anding Hospital，Chifeng City，Inner Mongolia，Chifeng 024000，China
杨会	YANG Hui	北京中医药大学中药学院，北京100029	School of Chinese Materia Medica，Beijing University of Chinese Medicine，Beijing 100029，China
白云绮	BAI Yun-qi	北京中医药大学东直门医院中医内科学教育部和北京市重点实验室，北京100700	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
李慧	LI Hui	北京中医药大学中药学院，北京100029	School of Chinese Materia Medica，Beijing University of Chinese Medicine，Beijing 100029，China
娄利霞	LOU Li-xia	北京中医药大学东直门医院中医内科学教育部和北京市重点实验室，北京100700	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
赵一舟	ZHAO Yi-zhou	北京中医药大学东直门医院中医内科学教育部和北京市重点实验室，北京100700	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
吴爱明	WU Ai-ming	北京中医药大学东直门医院中医内科学教育部和北京市重点实验室，北京100700	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
图雅	TU Ya	中国中医科学院中医药发展研究中心，北京100700	Research Center for Chinese Medicine Development，China Academy of Chinese Medical Sciences，Beijing 100700，China
聂波	NIE Bo	北京中医药大学东直门医院中医内科学教育部和北京市重点实验室，北京100700	Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China	聂波，研究员，研究方向：中医药防治动脉粥样硬化及其作用机制，中药药效物质质量标准及药物代谢；Tel：（010）84013190，E-mail：nieboww_1977@163.com

基金项目:国家自然科学基金青年基金课题（81403365）；国家自然科学基金面上项目（81874446）

中文摘要:目的：研究四妙勇安汤对高脂饲料喂养的ApoE基因敲除小鼠动脉粥样硬化炎症反应的干预作用。方法：采用高脂饲料喂养ApoE-/-小鼠14周制备动脉粥样硬化模型，成模后随机分为5组：模型组，阳性药组（阿托伐他汀，2.57 mg·kg-1），四妙勇安汤高剂量组（34.9 g·kg-1）、四妙勇安汤中剂量组（23.14 g·kg-1）和四妙勇安汤低剂量组（11.61 g·kg-1），分别灌胃给药12周，同时以C57BL/6 小鼠为正常对照组，给予去离子水灌胃12周。采用生化仪检测三酰甘油（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）含量；HE染色观察主动脉血管形态，并测量主动脉内膜厚度（IT）、中膜厚度（MT）、血管管腔面积（LA）、粥样斑块面积（PA）、内中膜厚度比（IT/MT）、管腔狭窄率（PA/LA）；采用流式高通量多因子检测技术检测血清中白介素-6（IL-6）、单核细胞趋化蛋白-1（MCP-1）炎症细胞因子表达。结果：与对照组相比，模型组小鼠血清TC、TG、LDL-C明显提高，HDL-C明显降低，PA、IT及IT/MT明显升高（P<0.01）。与模型组比较，四妙勇安汤能够明显降低ApoE-/-小鼠主动脉PA、IT及IT/MT（P<0.01），并明显降低IL-6及MCP-1表达（P＜0.01、P＜0.05），但对血脂水平无明显的影响。结论：四妙勇安汤可以通过抑制炎症反应防治动脉粥样硬化，而不依赖血脂水平的变化。

中文关键词:四妙勇安汤动脉粥样硬化 ApoE-/-小鼠病理白介素-6 单核细胞趋化蛋白-1

Effect of Simiao Yongan Decoction on IL-6 and MCP-1 in ApoE-/-Atherosclerotic Mice

Abstract:Objective：To study the intervention effect of Simiao Yongan decoction on atherosclerotic inflammatory response in ApoE knockout mice fed with high fat diet.Methods：ApoE-/-mice were fed with high-fat diet for 14 weeks to prepare atherosclerosis model.After modeling，they were randomly divided into 5 groups：model group，positive drug group（atorvastatin，2.57 mg·kg-1），Simiao Yongan decoction high dose group（34.9 g·kg-1），Simiao Yongan decoction medium dose group（23.14 g·kg-1）and Simiao Yongan low dose group（11.61 g·kg-1），respectively，administered by stomach 12 weeks.At the same time，C57BL/6 mice were used as the normal control group，and deionized water was administered for 12 weeks.Using biochemical analyzer to detect triglyceride（TG），total cholesterol（TC），high-density lipoprotein cholesterol（HDL-C）and low-density lipoprotein cholesterol（low-density lipoprotein cholesterol，LDL-C）content；HE staining to observe aortic vascular morphology，and measurement of aortic intima thickness（IT），medial thickness（MT），vascular lumen area（LA），atheroma area（PA）intima-media thickness ratio（IT/MT），lumen stenosis rate（PA/LA）；interleukin-6（IL-6）and mononuclear serum，and expression of inflammatory cytokines by monocyte chemoattractant protein-1（MCP-1）were measured by flow-through high-throughput multifactor detection.Results：Compared with the control group，serum TC，TG and LDL-C in the model group were significantly increased，HDL-C was significantly decreased，and PA，IT and IT/MT were significantly increased（P<0.01）.Compared with the model group，Simiao Yongan decoction significantly reduced PA，IT and IT/MT（P<0.01）in ApoE-/-mice，and significantly decreased IL-6 and MCP-1 expression（P<0.01，P<0.05），but had no significant effect on blood lipid levels.Conclusion：Simiao Yongan decoction can prevent atherosclerosis by inhibiting inflammatory response，independent of changes in blood lipid levels.

keywords:Simiao Yongan decoction atherosclerosis ApoE-/-mice pathology IL-6 MCP-1

查看全文查看/发表评论下载PDF阅读器